ENDRA Life Sciences (NASDAQ:NDRA – Get Free Report) and Gadsden Properties (OTCMKTS:GADS – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.
Volatility and Risk
ENDRA Life Sciences has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500. Comparatively, Gadsden Properties has a beta of -5.57, suggesting that its stock price is 657% less volatile than the S&P 500.
Valuation and Earnings
This table compares ENDRA Life Sciences and Gadsden Properties”s revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
ENDRA Life Sciences | N/A | N/A | -$10.06 million | ($901.15) | 0.00 |
Gadsden Properties | N/A | N/A | N/A | N/A | N/A |
Profitability
This table compares ENDRA Life Sciences and Gadsden Properties’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
ENDRA Life Sciences | N/A | -127.39% | -103.77% |
Gadsden Properties | N/A | N/A | N/A |
Analyst Recommendations
This is a breakdown of current ratings and target prices for ENDRA Life Sciences and Gadsden Properties, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
ENDRA Life Sciences | 0 | 0 | 1 | 0 | 3.00 |
Gadsden Properties | 0 | 0 | 0 | 0 | 0.00 |
ENDRA Life Sciences presently has a consensus target price of $700,000.00, suggesting a potential upside of 15,981,635.16%. Given ENDRA Life Sciences’ stronger consensus rating and higher probable upside, equities research analysts plainly believe ENDRA Life Sciences is more favorable than Gadsden Properties.
Insider & Institutional Ownership
1.2% of ENDRA Life Sciences shares are held by institutional investors. 0.0% of ENDRA Life Sciences shares are held by insiders. Comparatively, 5.0% of Gadsden Properties shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
ENDRA Life Sciences beats Gadsden Properties on 5 of the 8 factors compared between the two stocks.
About ENDRA Life Sciences
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
About Gadsden Properties
Gadsden Properties, Inc. is a Nevada corporation that was formed on December 28, 2010. Gadsden concentrates primarily on investments in high quality income-producing assets, residential developments and other opportunistic commercial properties in secondary and tertiary markets across the United States. The Company derives value from smaller, flexible retail investments that range from $5 million to $50 million and off-market mixed-use properties ranging from $50 million to $250 million. As a result of this chosen strategy, we believe that Gadsden is developing a unique competitive advantage that generally allows the Company to invest in markets and assets that are often overlooked by larger institutional investors, such as publicly-traded REITs and other large institutional investors. As part of its strategy, Gadsden attracts specific sellers that prefer the tax deferral advantages offered through issuing operating partnership units in exchange for their properties. These real estate assets are typically operated by independent owners that are seeking to monetize their real estate holdings, and who are typically not well capitalized or well-seasoned real estate operators. These transactions create a variety of outcomes for Gadsden and the sellers typically resulting in lease-up and value-added opportunities that may not be otherwise achieved.
Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.